TCGA-43-6771-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 85
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- TNFA_SIGNALING_VIA_NFKB+0.510
- ANGIOGENESIS+0.460
- HYPOXIA+0.460
- APICAL_SURFACE+0.450
- TGF_BETA_SIGNALING+0.440
- APICAL_JUNCTION+0.420
- HEDGEHOG_SIGNALING+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- P53_PATHWAY+0.420
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.350
- E2F_TARGETS-0.200
- DNA_REPAIR-0.190
- BILE_ACID_METABOLISM-0.140
- FATTY_ACID_METABOLISM-0.130
- SPERMATOGENESIS-0.110
- MYC_TARGETS_V2-0.070
- ADIPOGENESIS-0.040
- UNFOLDED_PROTEIN_RESPONSE-0.010
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8481-01A-11R-2326-07 | — | cohortSQ1 | 0.937 |
| 2 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.911 |
| 3 | TCGA-22-4609-01A-21R-2125-07 | — | cohortSQ1 | 0.890 |
| 4 | SRR10900576 | — | — | 0.887 |
| 5 | s0122159 | — | — | 0.883 |
| 6 | MNG918 | — | — | 0.870 |
| 7 | BS_TK84K675 | high-grade glioma | — | 0.870 |
| 8 | TCGA-77-8138-01A-11R-2247-07 | — | cohortSQ1 | 0.862 |
| 9 | C3L-02601 | — | cohortA1 | 0.860 |
| 10 | SRR26320076 | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| HYPOXIA | 0.460 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.450 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |